Combination of Osimertinib and Chemotherapy Enhances Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
Combining osimertinib with chemotherapy significantly extends progression-free and overall survival in patients with EGFR-mutated non-small cell lung cancer, according to recent clinical trial results.
Recent findings presented at the 2025 World Conference on Lung Cancer highlight the benefits of combining osimertinib with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. The COMPEL trial, a global double-blind study, evaluated patients who experienced non-central nervous system (CNS) disease progression on first-line osimertinib. Participants were randomized to receive either continued osimertinib alongside platinum-based chemotherapy or placebo with chemotherapy.
The study demonstrated that patients receiving osimertinib in combination with chemotherapy had a significantly longer progression-free survival (PFS), with a median of 8.4 months compared to 4.4 months in the placebo group. The hazard ratio for disease progression was 0.43, indicating a substantial reduction in risk. Additionally, overall survival was improved, with median overall survival reaching 15.9 months for the combination group versus 9.8 months for placebo plus chemotherapy.
Lead researcher Dr. Giulia Pasello from the Veneto Institute of Oncology explained that some tumor cells remain sensitive to continued osimertinib, supporting its use as a backbone treatment strategy in this setting. The combination therapy was well-tolerated, with safety profiles consistent with known effects of the individual agents. These promising results align with the findings from the FLAURA2 study, further emphasizing the potential of integrating osimertinib with chemotherapy for better patient outcomes.
This research underscores the importance of personalized treatment plans for patients with EGFR-mutated NSCLC post-progression, offering a new avenue to prolong disease control and improve survival rates.
Source: https://medicalxpress.com/news/2025-09-osimertinib-chemotherapy-free-survival-egfr.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Discovery of Key Proteins Associated with Rare Autoimmune Vasculopathy
Researchers have identified two proteins, CCN1 and CCN2, that play a crucial role in blood vessel thickening in autoimmune vasculopathy, a complication of antiphospholipid syndrome, opening new avenues for targeted treatments.
High Birth Weight Identified as Key Risk Factor for Serious Birth Injuries
New study finds high birth weight is a major risk factor for obstetric anal sphincter injuries, leading to long-term health impacts. Predictive models aim to improve childbirth safety.
Innovative At-Home Foot Recognition AI Device Aims to Reduce Heart Failure Hospitalizations
A groundbreaking AI device designed for home use can detect early signs of worsening heart failure by monitoring foot edema, potentially reducing hospitalizations and improving patient outcomes. Developed by Heartfelt Technologies, this innovative system offers a proactive approach to managing cardiovascular health.